TSCAN THERAP.INC.DL-,0001 Aktie

TScan treated the first patient in the phase‑3 ALLOHA‑2 trial with TSC‑101 after stem cell engraftment. The study is testing whether TSC‑101 prevents relapses after allogeneic hematopoietic cell transplantation in acute myeloid leukemia and myelodysplastic syndromes compared with transplantation alone. Assignment is based on biological factors: A02:01‑positive patients with a suitable donor receive the treatment; the primary endpoint is relapse‑free survival, and key secondary endpoints are overall and event‑free survival. Topline data are expected in mid‑2028; the trial is actively ongoing in the US (NCT07702578). » Más en de.investing.com

TScan Therapeutics has, following coordination with the FDA, begun recruitment for a registration‑enabling phase‑III study of TSC‑101; the primary endpoint is disease‑free survival, the trial is powered at 85% to detect a hazard ratio of 0.52 and uses a biologically assigned control group (HLA‑A02:01). Phase‑I data showed 100% disease‑free survival over three years in a small subgroup versus 0% in controls. A new, commercially suitable manufacturing process shortens production time from 17 to 12 days and reduces cell loss, which could improve the product profile. TScan holds $128 million in cash, expected to fund operations into the second half of 2027; for top‑line data expected by mid‑2028 the company is evaluating additional financing options or partnerships. » Más en de.investing.com

Leiden Dworak announces his resignation as vice president of finance and principal accounting officer, effective April 10, 2026; the company reports no disagreements. Jason A. Amello, the current chief financial officer, will assume the principal accounting officer responsibilities as of April 10 with no additional compensation or changes to existing agreements. In parallel, TScan reports completion of patient recruitment for cohort C of the Phase 1 ALLOHA study and FDA approvals of the INDs for TSC-102-A01 and TSC-102-A03; Phase 1 studies for both candidates are planned for the second half of 2026. » Más en de.investing.com